The lethal chicken mutation nanomelia leads to severe skeletal was not further processed; this is consistent with the conclusion defects because of a deficiency of aggrecan, which is the large that it moves no further along the secretory pathway than the aggregating chondroitin sulphate proteoglycan of cartilage. In ER. Using brefeldin A we demonstrated that the defective previous work, we have demonstrated that nanomelic chondroprecursor can function as a substrate for Golgi-mediated glycoscytes produce a truncated aggrecan precursor that fails to be aminoglycan chains, but does not do so in the nanomelic secreted, and is apparently arrested in the endoplasmic reticulum chondrocyte because it fails to be translocated to the appropriate (ER). In this study, we investigated the biosynthesis and extent membrane compartment. These studies illustrate how combined of processing of the abnormal aggrecan precursor. The truncated cell biological/biochemical and molecular investigations may precursor was translated directly in cell-free reactions, indicating contribute to our understanding of the biological consequences that it does not arise post-translationally. Further studies addresand molecular basis of genetic diseases, particularly those sed the processing capabilities of the defective precursor. We involving errors in large, highly modified molecules such as found that the mutant precursor was modified by N-linked, proteoglycans. mannose-rich oligosaccharides and by the addition of xylose, but
INTRODUCTION
the level of hydration and thereby provide an expanded tissue volume for bone replacement during long-bone development. Recent studies highlight how important sequential processing Without aggrecan, the intercellular, matrix-filled spaces are and assembly events and movement through specific compartgreatly reduced, the cartilage model fails to expand,and consements of the secretory pathway are for normal protein function quently, the growth of long bones is seriously impaired. Aggrecan (Rose and Doms, 1988; Hurtley and Helenius, 1989; Farquhar, function principally reflects the more than 100 covalently at-1991). By extrapolation, diseases may arise as a consequence of tached chondroitin sulphate (CS) and keratan sulphate (KS) errors in these processes. For example, problems of synthesis, glycosaminoglycan chains that are the result of complex biosynassembly and intracellular trafficking are implicated in the basic thetic processes involving thousands of co-and post-translational mechanisms underlying lysosomal storage diseases, familial reactions (reviewed recently by Wight et al., 1991; Hardingham hypercholesterolaemia , and cystic fibrosis (Amara et al., 1992) .
and Fosang, 1992) . The large (> 200 kDa) aggrecan core protein In connective-tissue disorders such as osteogenesis imperfecta is only 10 % of the molecular mass of the fully processed and chondrodystrophies, defects may involve the abnormal proteoglycan, which is modified as well by N-and 0-linked synthesis, processing, translocation and assembly of extracellular oligosaccharides. The chondrocyte is characterized by an exmatrix (ECM) molecules (Goetinck, 1983; Stanescu et al., 1984;  tensive endoplasmic reticulum (ER) and Golgi, as expected for a Johnson, 1986; Prockop, 1990; Spranger and Martoux, 1990;  cell heavily committed to the production of highly modified Byers et al., 1991) . These types of errors might be expected for ECM molecules in large quantities. The synthetic, processing ECM molecules, as they are mostly large, highly modified and and assembly events are accomplished in several subcompartstrongly interactive, and are characteristically assembled into ments of the secretory pathway that have been described in extensive macromolecular arrays. Although defects in the colprevious studies (Pacifici et al., 1984; Vertel and Barkman, 1984 ; lagens have frequently been found (Prockop, 1990; Byers et al., Vertel and Hitti, 1987; Campbell and Schwartz, 1988; Vertel et 1991) , proteoglycans and other matrix molecules are also al., 1985a ,b, 1989 , 1993a Kearns et al., 1993) , although some candidates for these genetic diseases (Goetinck, 1983; Stanescu features of intracellular processing and assembly are not yet well et Johnson, 1986; Spranger and Martoux, 1990) .
defined. Structural studies of aggrecan from several species Nanomelia is one such genetic mutation that causes shortened (including chicken) have provided the complete coding sequence limbs, other skeletal abnormalities and death in chicken embryos and a clear definition of several domains (see Figure 6 ); these as a result of the absence of aggrecan in cartilage ECM include three highly conserved globular domains, GI and G2 at (Landauer, 1965; Pennypacker and Goetinck, 1976; the N-terminus, and G3 at the C-terminus, and the domains 1993b). involved in glycosaminoglycan chain substitution for KS and CS Aggrecan is associated with a network of type-IT collagen-(reviewed by Wight et al., 1991; Hardingham and Fosang, 1992;  containing fibrils in normal cartilage ECM where it contributes for chicken aggrecan, see Li et al., 1993; Chandrasekaran and localized concentrations of negative charges that serve to increase Tanzer, 1992).
Abbreviations used: BFA, brefeldin A; CS, chondroitin sulphate; ECM, extracellular matrix; ER, endoplasmic reticulum; FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KS, keratan sulphate; FCS, fetal-calf serum.
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In this article, we explore the biological consequences of the nanomelia defect. On the basis of previous work that reported the arrest of a truncated aggrecan precursor in the ER of the nanomelic chondrocyte (Vertel et al., 1993b) , we have investigated the origin of the truncated product, the extent of its compartment-specific processing and its potential for additional processing in studies that utilize cell-biological, biochemical and molecular techniques. In concomitant studies reported elsewhere, we identify the defect as a premature stop codon (Li et al., 1993 (Vertel and Dorfman, 1979; Vertel et al., 1993b) . FITC-coupled Bandeiraea simplicifolia lectin I was obtained from Vector (Burlingame, CA, U.S.A.).
Cell culture
Chondrocytes were prepared from the sterna of 16-day-old normal White Leghorn chicken embryos and embryos carrying the genetic mutation, nanomelia, as described previously (O'Donnell et al., 1988 
Cell-free translation
Protein synthesis in vitro was performed with rabbit reticulocyte lysate translation kits purchased from Promega. Individual reactions contained 16 ,Ci of [35S]methionine and 5-10 ,tg of total RNA per 20 1l of reaction mix, and were run under modified conditions that included incubation at 30 'C for 2 h in the presence of 0.4 mM phenylmethanesulphonyl fluoride, 1.2 mM magnesium acetate and 120 mM potassium acetate as described previously (Vertel and Hitti, 1987) .
Biosynthetic labelling of intact cells, immunoprecipitation and gel electrophoresis
Biosynthetic labelling of normal and nanomelic chondrocytes from 4-day-old suspension cultures was accomplished as described previously (O'Donnell et al., 1988) . Cells were pulselabelled for 5 min at 37 'C with 100,uCi of [35S]methionine and chased in 4 ml of medium containing an excess of unlabelled methionine or labelled for 2 h with 100,Ci of Na235SO . Cell aliquots were removed at the indicated times, collected by centrifugation in a microfuge, washed with cold Hanks' balanced salt solution by repeated suspension and centrifugation, and treated for immunoprecipitation or for gel electrophoresis. Immunoprecipitations of cell-synthesized and cell-free translated products with S103L, and SDS/PAGE were as described previously (Vertel and Hitti, 1987; O'Donnell et al., 1988) . For determinations ofchondroitinase sensitivity, immunoprecipitates of radiolabelled products were resuspended in 40,tl of 0.06 M sodium acetate/0.05 M Tris, pH 7.5 containing 0.020% azide, divided into two aliquots and incubated for 3 h at 37 'C in the presence or absence of 0.25 units/ml chondroitinase. Samples were then treated for SDS/PAGE.
Xylosylation
Semi-intact cells were prepared from chondrocytes grown in monolayer culture using described permeabilization procedures and conditions for labelling (Beckers et al., 1987; Kearns et al., 1993; Vertel et al., 1993a) . Briefly, cells were swollen in hypotonic buffer (15 mM KCl, 50 mM Hepes, pH 7.2) for 10 min on ice and permeabilized by scraping from the dish with a rubber policeman in 'breaking buffer' (90 mM KCl, 50 mM Hepes, pH 7.2). On the basis of the uptake of Trypan Blue, > 95 % permeabilization was achieved. Semi-intact chondrocytes were labelled with 30,Ci of UDP-[14C]xylose for 15 min at 37 'C.
Immunofluorescence and lectin localization
At day 5 of culture, chondrocytes in monolayer culture were fixed with 75 % (v/v) ethanol and processed for immunofluorescence staining with rabbit polyclonal antibodies raised to aggrecan as previously described (Vertel and Dorfman, 1979; Vertel et al., 1993b) . Immunolocalization was detected with FITC-coupled goat anti-(rabbit IgG). For lectin localization, ethanol-fixed chondrocytes were incubated with FITC-coupled Bandeiraea simplicifolia lectin I, which recognizes a-galactosyl residues (Hayes and Goldstein, 1974 (1987) . When RNA was used to direct protein synthesis in vitro, immunoprecipitable aggrecan-related precursors were detected among the products (Figure 1) . The core-protein precursor, migrating as a protein of 340 kDa, was translated from RNA of normal chondrocytes (Figure 1, lanes 1 and 3) (Vertel and Hitti, 1987; O'Donnell et al., 1988) . Recent methods developed to investigate xylose addition (Kearns et al., 1993; Vertel et al., 1993a) were applied in the study of nanomelic chondrocytes to determine whether the truncated core-protein precursor undergoes the enzymic reaction that initiates the synthesis of CS chains. Nanomelic chondrocytes were made semi-intact in order to bypass the permeability barrier normally imposed by the plasma membrane (Beckers et al., 1987; Balch, 1989) , thereby permitting direct access of nucleotide sugars to intracellular organelles. When semi-intact nanomelic chondrocytes were used in radiolabelling studies, UDP-[14C]xylose was incorporated into the truncated aggrecan precursor (Figure 2, lane 1) . The equivalent product immunoprecipitated from intact nanomelic chondrocytes labelled with [35S]methionine is shown for comparison (Figure 2, lane 2) . Thus, the aberrant core-protein precursor is modified by the addition ofmannose-rich oligosaccharides and xylose. Our recent studies identifying the late ER as the initial site of xylosylation in chondrocytes (Vertel et al., 1993a) are consistent with this conclusion.
Truncated aggrecan core protein can function as a substrate for CS chain elongation although it does not undergo this modffication in the nanomelic chondrocyte Experiments using the potent inhibitor BFA have played a pivotal role in elucidating the characteristics of ER-to-Golgi trafficking and distinguishing ER and Golgi functions (Klausner et al., 1992) . BFA interferes with forward movement through the secretory pathway without blocking retrograde movement from the Golgi back to the ER. In essence, the Golgi collapses down on the ER, and a hybrid ER-Golgi compartment capable of both ER-and Golgi-mediated (Figure 3) . In untreated cells, this lectin reacted with a restricted region of the perinuclear cytoplasm (Figure 3a) , which has been shown in previous studies to correspond to the Golgi (Vertel et al., 1993b (Figure 3b ). Once the Golgi reorganization was established for nanomelic chondrocytes in BFA, biochemical experiments were initiated to evaluate the processing capabilities of the truncated precursor. We observed that in the presence of BFA, nanomelic chondrocytes convert the mutant aggrecan precursor into a product of increasing size and heterogeneity, suggestive of more extensive post-translational processing (Figure 4a ). The incorporation of sulphate into the heterogeneous processed form indicates that the modification includes the addition and elongation ofglycosaminoglycan chains ( Figure 4b , lane 1). This conclusion is further supported by the chondroitinase sensitivity exhibited by the modified product ( Figure 4b , lane 2). In Figure 5 (a), immunofluorescence staining with antibodies that recognize aggrecan and its precursors demonstrates the localization ofthe truncated aggrecan precursor within ER subcompartments in nanomelic chondrocytes and its absence from the region of the perinuclear Golgi. In the presence of BFA, the modified product continues to reside in sites throughout the cytoplasm ( Figure Sb) . Thus, although the product is biochemically modified when the nanomelic chondrocyte is treated with BFA, its cytoplasmic distribution is not altered. We conclude that the nanomelic precursor is capable of being modified by Golgi-mediated processing events but, without experimental intervention, is not accessible to the required Golgi enzymes.
DISCUSSION
Experiments to date support the hypothesis that nanomelic chondrocytes produce a truncated aggrecan precursor that moves no further in the secretory pathway than the ER, and is perhaps degraded there. For example, normal chondrocytes produce a 370 kDa core-protein precursor that, with time, is converted into fully processed aggrecan, a highly modified product of (1-5) x 106 Da. In contrast, pulse-labelling ofnanomelic chondrocytes revealed a 300 kDa precursor that disappeared with time of chase. No larger processed or secreted forms were detected (O'Donnell et al., 1988) . Immunolocalization studies demonstrated that the defective precursor is contained within smoothmembrane-limited subcompartments of the ER, but was never observed in the perinuclear Golgi or in the ECM (Vertel et al., 1993b ). As we show in this report, the synthesis of a truncated precursor in cell-free translation reactions is directed by RNA from nanomelic chondrocytes. This finding establishes that the defective product is specified by information encoded directly in the mRNA, and does not arise by a post-translational mechanism. The conclusion is further supported by our recent studies that define the molecular basis of nanomelia as a G to T transversion leading to a premature stop (Li et al., 1993) . Since the truncated aggrecan precursor is arrested in the ER, the nanomelic chondrocyte offers a unique model for the systematic study of compartment-specific modifications that occur during the early stages of aggrecan biosynthesis and processing. The differences in electrophoretic mobilities between the cell synthesized and cell-free translated precursors, combined with the previously reported endoglycosidase H sensitivity of the cell-synthesized products (O'Donnell et al., 1988) , verify the presence of mannose-rich oligosaccharides which are known to be added co-translationally (Kornfield and Kornfield, 1985) .
Experiments using semi-permeabilized nanomelic chondrocytes show that the truncated precursor is xylosylated, indicating that it acts as a competent substrate for the xylosylation machinery in a manner analogous to that of normal core protein. Furthermore, as all evidence indicates that the truncated precursor is arrested in the ER, this result is consistent with the view that xylosylation occurs in the ER, and adds additional support to recent subcellular fractionation and electron microscopic autoradiography studies that show xylosylation to be a late ER-to-early Golgi-mediated process (Kearns et al., 1993; Vertel et al., 1993a) .
The lack of further processing is interpreted as a failure of the truncated nanomelic precursor to be translocated to the Golgi where, presumably, processing would normally continue. Since the defective precursor never arrives in the Golgi, it is difficult to determine whether or not it is capable of being further processed. To circumvent this problem, BFA was employed. Through a mechanism that apparently interferes with vesicle coating, this inhibitor blocks forward movement from the ER to the Golgi, causes most of the Golgi to fuse with the ER, and leads to the formation of a hybrid ER-Golgi capable of many activities normally associated with Golgi function (Klausner et al., 1992) . In nanomelic chondrocytes treated with BFA, the truncated precursor became modified by the addition of sulphated, chondroitinase-sensitive glycosaminoglycan chains. Although significant biochemical processing occurred, the modified mutant precursor still remained localized within cytoplasmic subcompartments characteristic of the ER (in BFA-treated cells, these sites correspond to the hybrid ER-Golgi fusion compartment). We conclude that without experimental intervention, processing fails to continue because the Golgi enzymes that mediate these reactions do not come into contact with the mutant substrate.
The comparison of size on the basis of the relative electrophoretic mobilities of the cell-synthesized and cell-free translated aggrecan precursors suggests that the truncated precursor is approx. 20 % smaller than the normal aggrecan core protein, while direct comparison of coding sequences indicates that the mutant precursor is 30% smaller. This agreement is reasonable in light of the differences in experimental methods used to derive these percentages. Although it is useful to make comparisons of aggrecan core proteins (and the truncated precursor of nanomelic chondrocytes) based on masses determined from the electrophoretic mobilities of protein standards, the core-protein molecular mass of approx. 224 kDa calculated from the complete coding sequence (Li et al., 1993) indicates that these values are overestimates. Nonetheless, comparisons of either the coding sequences or the protein precursors predict that the defect is Gl IGD G2 KS Cs G3 S103L NANO stop Figure 6 The domain structure of aggrecan
The domain diagram of aggrecan from Hardingham and Fosang (1992) Figure 5 from Li et al., 1993) .
As a consequence of the premature stop codon that we recently identified at amino acid 1513 (Li et al., 1993) , the truncated precursor synthesized by the nanomelic chondrocyte is missing the entire G3 domain and the C-terminal part of the CS domain while retaining the GI, G2 and KS domains ( Figure 6 ). (Wiedemann et al., 1984; Paulsson et al., 1987) , and molecular analyses have established shared sequence identities for the N- terminal portion of the G3 domain with the hepatic lectin, and the C-terminal portion with complement regulatory protein (Sai et al., 1986; Doege et al., 1987) . Specific, low-affinity interactions with several sugar ligands have been reported for the expressed domain (Halberg et al., 1988) . The interpretation of these characteristics in the framework of extracellular function has led to the proposal that the domain may function in ECM assembly through interactions with carbohydrate moieties of other ECM molecules.
Although extracellular functions of the G3 domain have been emphasized in previous work, our studies suggest that intracellular functions of the missing domains need to be considered seriously. Many proteins require specific conformational changes in order to exit from the ER (Rose and Doms, 1988; Hurtley and Helenius, 1989; Pelham, 1989) . The globular nature of the G3 domain indicates that it is a highly folded region of the core protein and perhaps the achievement of its native conformation is required for movement out of the ER. Alternatively, the missing region may be involved in interactions (either with other domains or with different molecules) that must be completed before the precursor can leave the ER. As another possibility, some aspect of the missing region may function as a signal for translocation. We previously suggested that the premature stop codon might result in the exposure of an ER retention signal, but an examination of the newly created C-terminal sequence on the truncated precursor, VHETSG, shows that it bears no resemblance to the standard KDEL ER retention signal (Pelham, 1989) . The possibility of the existence of other, as yet unidentified, retention or recognition signals, however, is not ruled out. It is unlikely that the epidermal growth factor-like domain is required, as this domain exists as an alternatively spliced form in the chick (Li et al., 1993) and other aggrecan mRNAs (Fulop et al., 1993) .
It has been established that retention in the ER and targeting for degradation can be the consequence of a general cellular mechanism for quality control that operates if specific conformational and assembly events fail to occur (Rose and Doms, 1988; Hurtley and Helenius, 1989; Bonifacino and LippincottSchwartz, 1991) . Studies of viral glycoproteins and membrane receptor complexes have been particularly informative in advancing our understanding of this process. We can regard errors in the trafficking ofdefective cell products, such as those described for -the mutant nanomelic precursor, in this context. Related mechanisms have been implicated for several other genetic diseases, including familial hypercholesterolaemia, some forms of Tay-Sachs disease, and cystic fibrosis (Amara et al., 1992) . For example, one patient with Tay-Sachs disease accumulated gangliosides in lysosomes as a result of the production of a truncated precursor of the a-subunit of lysosomal /I-hexosaminidase that was retained and degraded in an early biosynthetic compartment (presumably the ER) rather than being delivered to the lysosome (Lau and Neufeld, 1989) .
Connective-tissue disorders may be considered similarly, as ECMs are composed of large, highly modified, strongly interactive macromolecules organized into characteristic assemblies. Many collagen defects have been associated with osteogenesis imperfecta, a number of chondrodystrophies and other diseases, and some proteoglycan defects have been suggested as well (Goetinck, 1983; Stanescu et al., 1984; Johnson, 1986; Prockop, 1990; Spranger and Martoux, 1990; Byers et al., 1991) . In many cases, the swollen appearance ofthe ER and biochemical evidence of delayed secretion and impaired ECM deposition reflect errors in synthesis, processing and assembly. A detailed analysis of the intracellular mechanisms involved in the ER retention of abnormal type-I procollagen was reported in a recent study of fibroblasts from a patient with osteogenesis imperfecta (Chessler and Byers, 1992 ). Our studies demonstrate the first mutation of an aggrecan gene that exhibits similar characteristics. It is likely that further investigations of this nature will reveal more about the underlying defects and consequences of genetic diseases, and about basic biological processes.
